OBJECTIVES: The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretroviral therapy (HAART) in an Italian cohort. METHODS: We included in the study patients from the Italian COhort Naïve Antiretrovirals (ICoNA) who initiated HAART when naïve to antiretroviral therapy (ART). The endpoints were discontinuation within the first year of >or= 1 drug in the first HAART regimen for any reason, intolerance/toxicity, poor adherence, immunovirological/clinical failure and simplification. We investigated whether the time of starting HAART (stratified as 'early', 1997-1999; 'intermediate', 2000-2002; 'recent', 2003-2007) was associated with the probability of reaching the endpoints by a survival analysis. RESULTS: Overall, the 1-year probability of discontinuation of >or= 1 drug in the first regimen was 36.1%. The main causes of discontinuation were intolerance/toxicity (696 of 1189 patients; 58.5%) and poor adherence (285 of 1189 patients; 24%). The hazards for all-reason change were comparable according to calendar period [2000-2002, adjusted relative hazard (ARH) 0.82, 95% confidence interval (CI) 0.69-0.98; 2003-2007, ARH 0.94, 95% CI 0.76-1.16, vs. 1997-1999; global P-value = 0.08]. Patients who started HAART during the 'recent' period were less likely to change their initial regimen because of intolerance/toxicity (ARH 0.67, 95% CI 0.51-0.89 vs. 'early' period). Patients who started in the 'intermediate' and 'recent' periods had a higher risk of discontinuation because of simplification (ARH 15.26, 95% CI 3.21-72.45, and ARH 37.97, 95% CI 7.56-190.64, vs. 'early' period, respectively). CONCLUSIONS: It seems important to evaluate reason-specific trends in the incidence of discontinuation in order to better understand the determinants of changes over time. The incidence of discontinuation because of intolerance/toxicity has declined over time while simplification strategies have become more frequent in recent years. Intolerance/toxicity remains the major cause of drug discontinuation.
OBJECTIVES: The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretroviral therapy (HAART) in an Italian cohort. METHODS: We included in the study patients from the Italian COhort Naïve Antiretrovirals (ICoNA) who initiated HAART when naïve to antiretroviral therapy (ART). The endpoints were discontinuation within the first year of >or= 1 drug in the first HAART regimen for any reason, intolerance/toxicity, poor adherence, immunovirological/clinical failure and simplification. We investigated whether the time of starting HAART (stratified as 'early', 1997-1999; 'intermediate', 2000-2002; 'recent', 2003-2007) was associated with the probability of reaching the endpoints by a survival analysis. RESULTS: Overall, the 1-year probability of discontinuation of >or= 1 drug in the first regimen was 36.1%. The main causes of discontinuation were intolerance/toxicity (696 of 1189 patients; 58.5%) and poor adherence (285 of 1189 patients; 24%). The hazards for all-reason change were comparable according to calendar period [2000-2002, adjusted relative hazard (ARH) 0.82, 95% confidence interval (CI) 0.69-0.98; 2003-2007, ARH 0.94, 95% CI 0.76-1.16, vs. 1997-1999; global P-value = 0.08]. Patients who started HAART during the 'recent' period were less likely to change their initial regimen because of intolerance/toxicity (ARH 0.67, 95% CI 0.51-0.89 vs. 'early' period). Patients who started in the 'intermediate' and 'recent' periods had a higher risk of discontinuation because of simplification (ARH 15.26, 95% CI 3.21-72.45, and ARH 37.97, 95% CI 7.56-190.64, vs. 'early' period, respectively). CONCLUSIONS: It seems important to evaluate reason-specific trends in the incidence of discontinuation in order to better understand the determinants of changes over time. The incidence of discontinuation because of intolerance/toxicity has declined over time while simplification strategies have become more frequent in recent years. Intolerance/toxicity remains the major cause of drug discontinuation.
Authors: Feifan Liu; Richeek Pradhan; Emily Druhl; Elaine Freund; Weisong Liu; Brian C Sauer; Fran Cunningham; Adam J Gordon; Celena B Peters; Hong Yu Journal: J Am Med Inform Assoc Date: 2019-10-01 Impact factor: 4.497
Authors: Laurence Slama; Xiuhong Li; Todd Brown; Lisa P Jacobson; Gilles Pialoux; Bernard Macatangay; Robert K Bolan; John Phair; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: Jennifer P Freeling; Josefin Koehn; Cuiling Shu; Jianguo Sun; Rodney J Y Ho Journal: AIDS Res Hum Retroviruses Date: 2015-01 Impact factor: 2.205
Authors: Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng Journal: Antivir Ther Date: 2018
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg Journal: HIV Med Date: 2014-09-01 Impact factor: 3.180
Authors: Alejandro Gonzalez-Serna; Keith Chan; Benita Yip; William Chau; Rachel McGovern; Hasina Samji; Viviane Dias Lima; Robert S Hogg; Richard Harrigan Journal: J Antimicrob Chemother Date: 2014-04-15 Impact factor: 5.790